Vaccine Info

Meningococcal Vaccines

Authored by
Staff
Last reviewed
September 28, 2021
Fact checked by
Robert Carlson, MD
Share

Meningococcal Vaccines Overview

The current Advisory Committee on Immunization Practices (ACIP) Meningococcal Vaccine Recommendations are published on this CDC webpage.

This CDC report published in September 2020 also contains new recommendations for administering booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed based on the availability of new data or licensure of new meningococcal vaccines.

Quadrivalent Meningococcal Conjugate (MenACWY) Vaccines

Menactra vaccine is for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in persons 9 months through 55 years of age.

Menveo vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.  Menveo is approved for use in persons 2 months through 55 years of age.

MenQuadfi vaccine is indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is approved for use in individuals 2 years of age and older.

Serogroup B Meningococcal (MenB) Vaccines

Trumenba vaccine is for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for individuals 10-25 years of age.

Bexsero is a vaccine to prevent invasive disease caused by Neisseria meningitidis serogroup B. Bexsero was approved for use in 2015 for individuals 10 through 25 years of age. 

Two additional licensed meningococcal vaccines are no longer available in the United States: 1) a quadrivalent (serogroups A, C, W, and Y) meningococcal polysaccharide vaccine (MPSV4) (Menomune – A/C/Y/W-135) and 2) a combined Haemophilus influenzae type b and meningococcal serogroups C and Y conjugate vaccine (Hib-MenCY-TT) (MenHibrix).

Meningococcal Vaccine News

September 28, 2021 - The World Health Organization and partners announced urgent action is needed to address meningitis, while launching the first-ever global strategy to battle the disease, called the Global Roadmap to Defeat Meningitis by 2030. The new meningitis strategy aims to save more than 200,000 lives annually

ACIP Meningococcal Vaccination Recommendations

ACIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years.

The ACIP also recommends routine vaccination with MenACWY for persons aged ≥2 months at increased risk for meningococcal disease caused by serogroups A, C, W, or Y, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor (e.g., eculizumab [Soliris] or ravulizumab [Ultomiris]); persons who have anatomic or functional asplenia; persons with human immunodeficiency virus infection; microbiologists routinely exposed to isolates of Neisseria meningitidis; persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroups A, C, W, or Y; persons who travel to or live in areas in which meningococcal disease is hyperendemic or epidemic; unvaccinated or incompletely vaccinated first-year college students living in residence halls; and military recruits. ACIP recommends MenACWY booster doses for previously vaccinated persons who become or remain at increased risk.

Also, ACIP recommends routine use of MenB vaccine series among persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor; persons who have anatomic or functional asplenia; microbiologists who are routinely exposed to isolates of N. meningitidis; and persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroup B.

The ACIP recommends MenB booster doses for previously vaccinated persons who become or remain at increased risk. In addition, ACIP recommends a MenB series for adolescents and young adults aged 16–23 years based on shared clinical decision-making to provide short-term protection against disease caused by most strains of serogroup B N. meningitidis.

Clinical Trials

No clinical trials found